Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Dasatinib + Quercetin (Senolytic Stack) | Resveratrol | |
|---|---|---|
| Category | Pharmaceuticals | Supplements |
| Standard Dose | Research indicates Dasatinib 100 mg + Quercetin 1000-1250 mg orally for 2 consecutive days, repeated every 2-4 weeks (intermittent 'hit-and-run' dosing). | 250-500mg trans-resveratrol daily |
| Timing | Take both compounds together on dosing days, with or without food. The 'hit-and-run' approach exploits the fact that senolytic effect occurs rapidly but senescent cells take weeks to re-accumulate. Quercetin bioavailability is improved by fat co-ingestion. | Morning with a fat-containing meal. Often taken alongside NMN for synergistic sirtuin activation. |
| Cycle Duration | Ongoing intermittent cycles. Long-term safety data in healthy populations is limited. Typically used in periodic courses (e.g., 2 days per month for 3-6 months, then reassess). | ongoing |
| Evidence Level | moderate_human | moderate_human |
Dasatinib is a multi-kinase inhibitor (targeting SRC, ABL, c-KIT, PDGFR, and ephrin receptors) originally developed for chronic myeloid leukemia. Quercetin is a natural flavonoid that inhibits PI3K, serpine/PAI-2, BCL-xL, and other anti-apoptotic pathways. Together, they constitute a senolytic combination that selectively induces apoptosis in senescent cells by disabling the senescent cell anti-apoptotic pathways (SCAPs) that allow damaged, non-dividing cells to resist programmed cell death. Senescent cells accumulate with aging and secrete the SASP (senescence-associated secretory phenotype) — inflammatory cytokines, matrix metalloproteinases, and growth factors that drive tissue dysfunction. By clearing senescent cells, D+Q reduces SASP-driven chronic inflammation.
Research indicates Dasatinib 100 mg + Quercetin 1000-1250 mg orally for 2 consecutive days, repeated every 2-4 weeks (intermittent 'hit-and-run' dosing).
Take both compounds together on dosing days, with or without food. The 'hit-and-run' approach exploits the fact that senolytic effect occurs rapidly but senescent cells take weeks to re-accumulate. Quercetin bioavailability is improved by fat co-ingestion.
Ongoing intermittent cycles. Long-term safety data in healthy populations is limited. Typically used in periodic courses (e.g., 2 days per month for 3-6 months, then reassess).
Resveratrol activates SIRT1 (the longevity sirtuin) via allosteric binding, promoting deacetylation of PGC-1alpha (mitochondrial biogenesis), FOXO3 (stress resistance), and p53 (DNA repair). It inhibits NF-kB and COX-2, reducing chronic inflammation. Resveratrol also activates AMPK independently of SIRT1 and inhibits phosphodiesterases (PDEs), raising cAMP levels. It improves endothelial function via eNOS upregulation and NO production.
250-500mg trans-resveratrol daily
Morning with a fat-containing meal. Often taken alongside NMN for synergistic sirtuin activation.
ongoing
Fast buy links (we may earn a small commission at no extra cost).
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →